CV HAL - Octave Guinebretiere

Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study

Simon Lecerf , Octave Guinebretiere , Raphaël Bentegeac , Victoria Gauthier , Estelle Aymes et al.

The Lancet Regional Health - Europe, 2026, 62, pp.101607. ⟨10.1016/j.lanepe.2026.101607⟩

Article dans une revue hal-05536248v1

Updated Multiple Sclerosis Incidence in France, 2011–2021

Octave Guinebretiere , Chloé Pierret , Quentin Calonge , Edouard Januel , Celine Louapre et al.

Neurology, 2025, 104 (9), ⟨10.1212/WNL.0000000000213586⟩

Article dans une revue hal-05034515v1

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis

Dang Wei , Anna Freydenzon , Octave Guinebretiere , Karim Zaidi , Fen Yang et al.

EBioMedicine, 2025, 113, pp.105585. ⟨10.1016/j.ebiom.2025.105585⟩

Article dans une revue hal-05028859v1

Longitudinal comparative analysis of antidepressants and anti-anxiety medications in Alzheimer's and Parkinson's diseases: insights from French and British health records

Nadine Hamieh , Manon Ansart , Octave Guinebretiere , Béranger Lekens , Laurène Gantzer et al.

Journal of Affective Disorders, 2025, 382, pp.148-153. ⟨10.1016/j.jad.2025.04.094⟩

Article dans une revue hal-05786482v1

Recurrence and Mortality After a First Status Epilepticus

Quentin Calonge , Octave Guinebretiere , Thomas Nedelec , Aurélie Hanin , Francois Le Gac et al.

Neurology, 2025, 104 (12), ⟨10.1212/WNL.0000000000213693⟩

Article dans une revue hal-05281729v1

Incidence, mortality, and management of status epilepticus from 2012 to 2022: An 11‐year nationwide study

Quentin Calonge , Aurélie Hanin , Edouard Januel , Octave Guinebretiere , Thomas Nedelec et al.

Epilepsia, 2025, ⟨10.1111/epi.18627⟩

Article dans une revue hal-05276617v1

Time Trends in Incidence of Motor Neuron Diseases in France: A Comprehensive 14‐Year Nationwide Study (2010–2023)

Octave Guinebretiere , Quentin Calonge , Gaëlle Bruneteau , Maria‐del‐mar Amador , Thomas Nedelec

European Journal of Neurology, 2025, 32 (4), ⟨10.1111/ene.70156⟩

Article dans une revue hal-05039352v1

Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis

Octave Guinebretiere , Thomas Nedelec , Laurène Gantzer , Beranger Lekens , Stanley Durrleman et al.

Neurology, 2023, 101 (24), ⟨10.1212/WNL.0000000000207981⟩

Article dans une revue hal-04330030v1

Validation study of “Santé-Cerveau”, a digital tool for early cognitive changes identification

Constance Lesoil , Stéphanie Bombois , Octave Guinebretiere , Marion Houot , Mahsa Bahrami et al.

Alzheimer's Research and Therapy, 2023, 15, pp.1-13. ⟨10.1186/s13195-023-01204-x⟩

Article dans une revue hal-04513299v1

Impact du déremboursement des anticholinestérasiques sur la détection des patients atteints de démence jeune dans le SNDS

Léa Aguilhon , Marc Dibling , Octave Guinebretiere , Quentin Calonge , Thomas Nedelec

Congrès émois 2026, Mar 2026, Saint malo, France. Journal of Epidemiology and Population Health, 74, pp.203277, 2026, ⟨10.1016/j.jeph.2026.203277⟩

Poster de conférence hal-05757468v1

Réconcilier les méthodes d'identification des patients atteints de la maladie de Parkinson dans le Système National des Données de Santé

Léa Aguilhon , Octave Guinebretiere , Quentin Calonge , Thomas Nedelec

EPICLIN 2026 - Conférence Francophone d'Epidémiologie Clinique, May 2026, Montpellier, France

Poster de conférence hal-05757500v1

Early prediction of neurodegenerative diseases using large transnational electronic health records databases for better prevention

Octave Guinebretiere

Neurons and Cognition [q-bio.NC]. Sorbonne Université, 2025. English. ⟨NNT : 2025SORUS244⟩

Thèse tel-05376653v1